Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Abstract: A unit for mixing and dispensing an aerosol precursor composition, and containers to be dispensed therefrom. The unit includes a plurality of bulk material filling stations, the plurality of bulk material filling stations have at least one first filling station with aerosol former and at least one second filling station with a flavor material for creating the aerosol precursor. The unit also includes a bulk consumable pack staging a plurality of containers configured to receive the aerosol precursor, and a robot configured to retrieve a container from the bulk consumable pack and move the container through at least two dimensions to stop at least two of the plurality of bulk material filling stations.

Abstract: Methods and machines are provided for forming a five-sided carton of packages of smoking articles. A piece of film material is applied to a plurality of packages of smoking articles such that five sides of the plurality of packages are at least partially covered by the film material, but the sixth side remains uncovered. The film material is applied such that the group of packages is sufficiently tightly bound so that none of the packages may slip free from the carton. The sixth side of the plurality of packages in the carton remains exposed so that tax stamps may be easily applied. The film of material may be applied so that a gap is formed relative to the sixth side.

Abstract: Reconfigurable gaming tables and playing cards, such as card devices including thin, planar display devices, may be in communication with a processing device for randomly selecting card images stored in a data storage device for display on the display devices.

Abstract: The present disclosure relates to electronic smoking articles exhibiting improved moisture control of a reservoir contained therein. The reservoir can be formed of fibrous materials, such as cellulose acetate fiber, thermoplastic fiber, non-thermoplastic fiber, or a combination thereof. The disclosure further provides methods for forming electronic smoking articles and methods of packaging electronic smoking articles (including cartridges thereof) so as to improve moisture control of the reservoir.

Abstract: A product including a package is provided. One or more tobacco-containing articles may be received in the package. A power producer may be configured to produce an electrical current. An output mechanism may be configured to receive the electrical current from the power producer and output a perceptible effect. The perceptible effect may, for example, increase a consumer's interest in the product. A related method is also provided.

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Abstract: Described herein are a number of Ebola and Marburg monoclonal antibodies.

Abstract: Described herein are a number of Ebola monoclonal antibodies.

Abstract: A high chroma effect pigment includes a platelet substrate and an optical coating formed on the platelet substrate. The optical coating includes a first high refractive index layer, a second high refractive index layer on the first high refractive index layer, and a diffused third material having a range of diffusion between 100% to partial diffusion in the first high refractive index layer, the second high refractive index layer, or both the first and the second high refractive index layers. The first and second high refractive index layers independently have a refractive index of about >1.65. The diffused third material is SiO2 or a metal oxide is different than the first and second high refractive index layers.

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).½H2O, Form F of HCl salt of Compound (1).3H2O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.

Abstract: A detachable chassis base for a tactical rifle is presented. The lower chassis receiver assembly can have a detachable chassis base that substantially selectively attaches to the chassis receiver interface. The detachable chassis base can be completely removable, or it can be hingedly attached to provide access without completely removing the chassis base, or a combination thereof. Multiple combinations of parts included in the detachable chassis base are possible. Several variations and combinations are illustrated herein, although others are contemplated.

Abstract: A blank configured to form a package is provided. The blank may include a bottom panel, a top panel, and an overlapping panel having an edge region and an adjoining region positioned between the edge region and the top panel. The adjoining region of the overlapping panel overlaps and attaches to the bottom panel to form a compartment when formed into a package. The compartment may be employed to store a consumable product, such as cartridges for an aerosol delivery device. A related method for forming the blank into the package is also provided.

Abstract: Various embodiments are described herein for controlling the self-assembly process of paramagnetic particles and the final particle cluster size using a liquid-liquid interface. The number of paramagnetic particles within a particle cluster and coating at the liquid-liquid interface may be controlled by systematically varying the strength of an applied magnetic field gradient and the interfacial tension of the liquid-liquid interface.

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Abstract: A solution to mitigate organizational risks and exposure from damages and harm related to distracted driving. The invention includes a system, method, and devices that enable the organization to manage, monitor, and enforce corporate Mobile Device policies, in particular policies to deter and prevent distracted driving and encourage safe alternatives. A system for preventing distracted driving, including an Organizational Policy for anti-distracted driving including a rule and a Mobile Device configured to restrict, disable, or enable a feature of the Mobile Device based upon the rule.

Abstract: An accessory device (20) for a stroller has a body (42) with a central portion (44) between opposed free ends (46) of the body and has an infant car seat mount (120) carried on the body (42) near at least one of the free ends of the body (42). The accessory device (20) is configured to at least partially widthwise traverse a frame assembly of a stroller (10) when installed on the frame assembly. The accessory device (20) is selectively removable from and attachable to the frame assembly, whereby the infant car seat mount (120) is also removable from and attachable relative to the frame assembly in concert with the accessory device.